Search research articles
Contact Us
Filters
Showing results (101-110 of 260) with videos related to
Page
of 26
Sort By:
Current Opinion in Pharmacology
|
August 30, 2008
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises
Timothy A Yap, Michelle D Garrett, Mike I Walton, et al.
Expert Review of Anticancer Therapy
|
October 14, 2025
Drugging the DNA damage response in the clinic: going beyond PARP
Carlos Torrado, Alvaro Gonzalez-Ortiz, Camila B Xavier, et al.
Cancer Research
|
November 29, 2018
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen, Wei Zhao, Zhenlin Ju, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2024
Oncology Combination Drug Development Strategies for Project Optimus
Timothy A Yap, Julie Bullock, Susan Chong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A
Kyriakos P Papadopoulos, Meredith McKean, Silvia Goldoni, et al.
Journal for Immunotherapy of Cancer
|
June 18, 2025
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies
Jay Jacoby, Deva Mahalingam, Angela Alistar, et al.
JAMA Network Open
|
May 20, 2022
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
Timothy A Yap, Arya Ashok, Jessica Stoll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2025
A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
Lillian L Siu, Timothy A Yap, Sofia Genta, et al.
Cancer Chemotherapy and Pharmacology
|
December 27, 2015
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients
Rajiv Kumar, Shir Kiong Lu, Anna Minchom, et al.
British Journal of Cancer
|
May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
Geoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
Page
of 26
Search research articles
Search
Showing results (101-110 of 260) with videos related to
Sort By:
Page
of 26
Current Opinion in Pharmacology
|
August 30, 2008
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises
Timothy A Yap, Michelle D Garrett, Mike I Walton, et al.
Expert Review of Anticancer Therapy
|
October 14, 2025
Drugging the DNA damage response in the clinic: going beyond PARP
Carlos Torrado, Alvaro Gonzalez-Ortiz, Camila B Xavier, et al.
Cancer Research
|
November 29, 2018
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen, Wei Zhao, Zhenlin Ju, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2024
Oncology Combination Drug Development Strategies for Project Optimus
Timothy A Yap, Julie Bullock, Susan Chong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A
Kyriakos P Papadopoulos, Meredith McKean, Silvia Goldoni, et al.
Journal for Immunotherapy of Cancer
|
June 18, 2025
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies
Jay Jacoby, Deva Mahalingam, Angela Alistar, et al.
JAMA Network Open
|
May 20, 2022
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
Timothy A Yap, Arya Ashok, Jessica Stoll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2025
A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
Lillian L Siu, Timothy A Yap, Sofia Genta, et al.
Cancer Chemotherapy and Pharmacology
|
December 27, 2015
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients
Rajiv Kumar, Shir Kiong Lu, Anna Minchom, et al.
British Journal of Cancer
|
May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
Geoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
Page
of 26